Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium

IEC-specific or systemic reduction of p55TNFR mitigates TNF toxicity without loss of antitumor efficacy.

Read More

Biomedcode's President, Professor George Kollias, was elected full member of the Academy of Athens

In recognition of eminent scientific discoveries and contributions to science, Professor George Kollias was elected March 14th 2013, full member of...

Read More

Zyngenia, Inc. reports successful preclinical evaluation of a novel bispecific antibody

A novel bispecific antibody targeting TNF and Ang2 was evaluated in Biomedcode’s Tg197 model

Read More

Biomedcode is a partner in aDDRess an international Initial Training Network

The aDDRess ITN is a joint European program with a focus on the impact of Chromatin Dynamics on the DNA damage Response (DDR)

Read More

Biomedcode is a partner in CodeAge an international Initial Training Network

CodeAge is a research network focusing on molecular, cellular and systems biology aspects of ageing.

Read More

Biomedcode is a participant in TARKINAID a research project to fight chronic autoimmune diseases

TARKINAID an international consortium of organisations from EU & Brazil, develops new ways of treating chronic autoimmune diseases such as RA

Read More

Viron Therapeutics Inc. announced successful preclinical testing of VT-346 using Biomedcode's TG197 model

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study.

Read More